Evaluation of breast HER2+ cancer pathologic response after a taxan plus trastuzumab-based chemotherapy

• Published in: Gynécologie, obstétrique & fertilité Vol. 44; no. 7-8; pp. 396 - 402
• Main Authors: Komguem, L, Guilbert, P, Doublier, M, Guillemin, F
• Format: Journal Article
• Language: French
• Published: France 01.07.2016
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - chemistry; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Female; Humans; Ki-67 Antigen - analysis; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2 - analysis; Retrospective Studies; Taxoids - administration & dosage; Trastuzumab - administration & dosage; Treatment Outcome; Neoadjuvant chemotherapy; Cancer du sein; Chimiothérapie néoadjuvante; Pathologic complete response; Breast cancer; Réponse histologique complète; Trastuzumab
• ISSN: 1769-6682
• DOI: 10.1016/j.gyobfe.2016.06.007

In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response. Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test. The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%. The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.